Bioverativ Therapeutics Inc.;Puget Sound Blood Center
发明人:
申请号：
EP13735995.6
公开号：
EP2802668B1
申请日:
2013.01.12
申请国别(地区):
EP
年份:
2018
代理人:
摘要：
The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.
